Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more ...

ZUG, Switzerland, June 06, 2025--Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in ...

New data were recently published showing that SHR0302, better known as ivarmacitinib, is safe and effective to use in adolescent and adult patients against atopic dermatitis, the most common ...

Atopic dermatitis, the most common form of eczema, can lead to dry, itchy, and inflamed skin. It often comes and goes in flares. It affects people of all skin tones, but it doesn't always look ...

Kymera Therapeutics announced new clinical trials for KT-621, targeting atopic dermatitis and asthma, with data expected in 2025 and 2026. Quiver AI Summary Kymera Therapeutics has announced the ...

Atopic dermatitis is an allergy affecting approximately 10% of the Japanese population, with symptoms closely related to social stress. In socially active adults, the disease often becomes chronic.

A Quick Review Itchy patches of skin are the main sign of atopic dermatitis. To avoid scratching, moisturizers, topical medications, and stress management techniques may help.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive scratching, among patients of varying ages and races with atopic dermatitis ...

The randomized, double-blind, placebo-controlled ROCKET HORIZON study (ClinicalTrials.gov Identifier: NCT05651711) evaluated the safety and efficacy of rocatinlimab, an anti-OX40 antibody, in ...

For most people, the key to treating atopic dermatitis is to avoid triggers, moisturize the skin, and apply topical treatments as prescribed. But this does not always work for people with moderate ...

Article August 1, 2024 Supplements and Featured Publications Managing Atopic Dermatitis: Clinical Considerations, Payer Perspective, and 2024 Guidelines Volume ...

ADORING is Dermavant’s Phase 3 atopic dermatitis (AD) clinical development program for VTAMA® (tapinarof) cream, 1%, which consists of ADORING 1 (NCT05014568) and ADORING 2 (NCT05032859), as ...